

REFERENCES

- Amegadzie, B.Y.; Bossard, M.J.; Drake, F.H.; Gowen, M.; Hanning, C.R.; Jones, C.; Kurdyla, J.T.; Levy, M.A.; McNulty, D.E.; Thompson, S.K.; Tomasz, T.A. (1996):* Proteolytic activity of human osteoclast cathepsin K. Expression, purification, activation, and substrate identification. *Journal of Biological Chemistry*. 271(21): 12517-24.
- Amegadzie, B.Y.; Carr, S.A.; D'Alessio, K.; Hanning, C.R.; Ijames, C.; Jones, C.S.; Kurdyla, J.T.; McLaughlin, M.M.; McNulty, D.E.; McQueney, M.S. (1997).* Autocatalytic activation of cathepsin K. *Journal of Biological Chemistry*. 272(21): 60.
- Andren, L.; Dymling, J.F.; Hogeman, K.E. (1962):* Osteopetrosis acro-osteolytica: a syndrome of osteopetrosis, acro-osteolysis and open sutures of the skull. *Acta Chir Scand* 124: 496-507.
- Arnett, F.C.; Edworthy, S.M.; Bloch, D.A. et al. (1988):* The American Rheumatism Association 1987 Revised Criteria for the classification of rheumatoid Arthritis. *Arthritis Rheum*, 31: 35-24.
- Barthiow, R.; Coleman, L.; Conner, J.R.; Debouck, C.; Dodds, R.A.; Drake, F.H.; James, I.E.; Gowen, M.; Richardson, S. (1996):* Cathepsin K, but not cathepsins B, L, or S, is abundantly expressed in human osteoclasts. *Journal of Biological Chemistry* 271(21): 12511-12516.
- Bennet, R.M.; Holt, P.J.U.; Lewis, S.M. et al. (1988):* Role of the reticuloendothelial system in anemia of RA. *An Rheum Dis*, 33: 1487-1492.

- Breedveld, F.C.; Fibbe, W.E.; Hermans, O.A. et al., (1987):** Factor in fusing the incidence of infection in fatty's syndrome. Arch. Intern Med.; 147: 915 – 922.
- Bromme, D. and Okamoto, K. (1995):** Human cathepsin O2, a novel cysteine protease highly expressed in osteoclastomas and ovary. Molecular cloning, sequencing and tissue distribution. Biol. Chem. Hoppe, Seyler. 376 : 379 – 384.
- Brömme, D.; Okamoto, K. (1995):** Human cathepsin O2, a novel cysteine protease highly expressed in osteoclastomas and ovary. Molecular cloning, sequencing and tissue distribution. Biol Chem Hoppe Seyler, 376:379-384.
- Brooks, P. and Lee, G. (1997):** The therapy of rheumatoid disease. Clin rheumato, 15 : 389 – 914.
- Bühling, F.; Gerber, A.; Häckel, C.; Krüger, S.; Köhnlein, T.; Brömme D.; Reinhold, D.; Ansorge, F.; Welte, T. (1999):** Expression of cathepsin K in lung epithelial cells. Am J Respir Crit Care Med, 20:612-619.
- Chank, F. and Lim. P.A. (1997):** Rehabilitation in rheumatic disease. Clin. Rheumatol, 24: 443 – 453.
- Chapman, H.A.; Desnick, R.J.; Geib, B.D.; Heller, M.; Morton, C.; Shi, G.P.; Weremowicz, S. (1997).** Structure and chromosomal assignment of the human cathepsin K gene. Genomics. 41(2): 258-62.

- Cygler, M.; Lalumiere, M.; Menard, R.; Sivaraman, J. (1999).** Crystal structure of wild-type human procathepsin K. *Protein Science* 8(2): 283-90.
- Dacie and Lewis, *Practical Haematology*, 9th ed. (2001): P.528**
Westergren A (1921): Studies of the suspension stability of the blood in pulmonary tuberculosis. *Acta Medica Scandinavica*, 54: 274- 282.
- Dacie and Lewis, *Practical Haematology*, 9th ed. (2001): P. 20.** Drabkin DL, Austin JH (1932): Spectrophotometric studies, spectrometric constants for common haemoglobin derivatives in human, dog and rabbit blood. *Journal of Biological Chemistry* 98: 719.
- D'Alessio, K.J.; Debouck, C.M.; Janson, C.A.; LaLonde, J.M.; McQueney, M.S.; Orsini, M.J.; Smith, W.J. (1999).** The crystal structure of human procathepsin K. *Biochemistry* 38(3):862-9.
- Dayer, J.M.; Arend, W.P. (1997):** Cytokines and growth factors. In Kelly WN, Harris ED Jr, Ruddy S, Sledge CB (eds) *Textbook of Rheumatology*, 5th ed Philadelphia WB Saunders; p 267.
- Debouck, C.; Drake, F.H.; Gowen, M.; Rood, J.A Van Horn, S. (1997).** Genomic organization and chromosome localization of the human cathepsin K gene (CTSK). *Genomics* 41(2): 169-76.
- Dodds, R.A.; Connor, J.R.; Drake, F.H.; Gowen, M. (1999):** Expression of cathepsin K messenger RNA in giant cells and their precursors in human osteoarthritic synovial tissues. *Arthritis Rheum*, 42:1588-1593.

- Dodds, R.A.; Yamashita, D.S. (2000):** Cathepsin K and the design of inhibitors of cathepsin K. *Current Pharmaceutical Design*. 6(1)1-24.
- Drake, F.H.; Dodds, R.A.; James, I.E.; Connor, J.R.; Debouck, C.; Richardson, S.; Lee-Rykaczewski, E.; Coleman, L.; Rieman, D.; Barthlow, R.; Hastings, G.; Gowen, M. (1996):** Cathepsin K, but not cathepsins B, L, or S, is abundantly expressed in human osteoclasts. *J Biol Chem*, 271:12511-12516.
- Drossaers-Bakker, K.W. (2002):** Long term outcome in rheumatoid arthritis: A simple algorithm of baseline parameters can predict radiographic damage, disability and disease course at 12-year follow up. *Arthritis Rheum*. 47: 383.
- Duncan, A.G.; David, E.H.; Kullberg, J. et al. (1994):** The American Rheumatism Association revised criteria for the classification of rheumatoid arthritis. *Arthritis Rheum*, 31: 315-24.
- Edmonds, P.J.; Corbett, M.; Materazzi, M. et al. (1997):** Radiological finding in RA. *Clinical Rheumatology*, 52: 95-102.
- Everts, V.; Aronson, D.C.; Beertsen, W. (1985):** Phagocytosis of bone collagen by osteoclasts in two cases of pycnodysostosis. *Calcif Tissue Int*, 37:25-31.
- Finckh, A.; Simard, J.F.; Duryea, J. (2006):** The effectiveness of anti-tumor necrosis factor therapy in preventing progressive radiographic joint damage in rheumatoid arthritis: a population-based study. *Arthritis Rheum*; 54: 54-9.

- Firestein, G.S. (1997):** Etiology and pathogenesis of rheumatoid arthritis. Textbook of Rheumatology, ed 5. Edited by WN Kelley, ED Harris, S Ruddy, CB Sledge. Philadelphia, London, Toronto, Montreal, Sydney, Tokyo, W. B. Saunders Company, pp 851–897.
- Fisher, C.L. and Nakamura, R. (1976):** AVITEX-CRP, latex serology test for detection of C-reactive protein. Am J Clin Path, 66: 840.
- Garnero, P.; Borel, O.; Byrjalsen, I.; Ferreras, M.; Drake, F.H.; M.S.; Foged, N.T.; Delmas, P.D.; and Delaisse, J.M. (1998):** The collagenolytic activity of cathepsin K is unique among mammalian proteinases. J. Biol. Chem. 27: 32347 – 32352.
- Garnero, P.; Borel, O.; Ferreras, M.; Drake, F.H. (1998):** The collagenolytic activity of cathepsin K is unique among mammalian proteinases. J Biol Chem 1998; 273: 32347-32352.
- Gelb, B.D.; Edelson, J.G. and Denick, R.J. (1995):** Linkage of pycnodysostosis to chromosome 1q21 by homozygosity mapping. Nat Genet 10: 235-237.
- Gelb, B.D.; Shi, G.P. and Chapman, H.A. (1996).** Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency. Science 273; 1236-1238.
- Gladmann, D.; Korner, W.F.; Christellers, B. et al., (1992):** Psoriatic arthritis; Recent advances in pathogenesis and treatment. Rheum Dis Clin Am, 18-247.
- Goto, T.; Yamaza, T. and Tanaka, T. (2003):** Cathepsins in the osteoclast. J Electron Microsc (Tokyo); 52: 551-558.

- Hara, K.S.; Ballard, D.J.; Histrum, D.M. et al., (1990):** Rheumatoid pericarditis: clinical features and survival. *Medicine* 69; 81-91.
- Harris, E.D.J.; Glauert, A.M. and Murley, A.H. (1977):** Intracellular collagen fibers at the pannus-cartilage junction in rheumatoid arthritis. *Arthritis Rheum*, 20:657-665.
- Harris, E.N.; Ghravi, A.E.; Hughes, G.R.V. et al. (1985):** Antiphospholipid antibodies. *Clin Rheum Dis*, 11: 591-598.
- Harris, E.D. (1997):** Rheumatoid Arthritis. Philadelphia, London, Toronto, Montreal, Sydney, Tokyo, W. B. Saunders Company.
- Herbier, L.C. and Heufelder, A.C. (2001):** Role of receptor activator of nuclear factor – κ B ligand and osteoprotegerin in bone cell biology *J Mol Med*. 79: 243-253.
- Hessian, P.A.; Hightlon, J.; Kean, A. (2003):** Cytokine profile of the rheumatoid nodules suggests that it is a Th-1 granuloma. *Arthritis Rheum* 48: 334-8.
- Hochberg, M.C.; Change, R.W.; Dwosh, I. et al. (1992):** The American Collage of Rheumatology and revised criteria for the classification of global functional capacity status in rheumatoid arthritis. *Arthritis Rheum*, 35 (5): 498-502.
- Hou, W-S.; Bromme, D.; Zhao, Y.; Mehler, E.; Dushey, C.; Weinstein, H.; Miranda, C.S.; Fraga, C.; Greig, F.; Carey, J.; Rimoin, D.L.; Desnick, R.J. and Gelb, B.D. (1999):** Cathepsin K: characterization of novel mutations in the pro and mature polypeptide regions causing pycnodysostosis. *J. Clin. Invest*, 103 : 731 – 738.

Hou, W.S.; Li, Z.; Gordon, R.E. et al. (2001): Cathepsin K is a critical protease in synovial fibroblast-mediated collagen degradation. *Am J Pathol*; 159: 2167-2177.

Hou, W.S.; Li Z.; Keyszer, G.; Weber, E.; Levy, R.; Klein, M.J. Gravallesse, E.M.; Goldring, S.R. and Bromme, D. (2002): Comparison of cathepsin K and S expression within the rheumatoid and osteoarthritic synovium. *Arthritis Rheum*, 46: 663-674.

Hou, W.S.; Li, Z.; Buttner, F.H. et al (2003): Cleavage site specificity of cathepsin K toward cartilage proteoglycans and protease complex formation. *Biol Chem*; 384: 891-897.

Huaselmann, H.J.; Flechtenmacher, J.; Hichal, L. (1996): Treatment of Rheumatoid Arthritis: New Therapeutic Approach with Biological Agents. *Arthritis Rheum*, 39: 478.

Huchinson, R.M.; Davis, P.; Jayson, M.I.; et al. (1988): thrombocytosis in RA. *Ann Rheum Dis*; 35: 138-145.

Hummel, K.M.; Petrow, P.K.; Franz, J.K.; Muller-Ladner, U.; Aicher, W.K.; Gay, R.E.; Brömme, D.; Gay, S. (1998): Cysteine proteinase cathepsin K mRNA is expressed in synovium of patients with rheumatoid arthritis and is detected at sites of synovial bone destruction. *J Rheumatol*, 25:1887-1894.

Hummel, K.M.; Petrow, P.K.; Ranz, J.K.; Maller-Lander, U.; Aicher, W.K.; Gay, R.E. and Bramme. (1998): Cathepsin K mRNA is expressed in synovium of patients with rheumatoid arthritis and bone destruction. *J Rheumatol*. 25 : 1887 – 1894.

- Husby, (1985):** Amyloidosis in RA. *Ann Clin Res*, 7: 154-159.
- Ishikawa, T.; Kamiyama, M.; Tani-Ishii, N. et al. (2001):** Inhibition of osteoclast differentiation and bone resorption by Cathepsin K antisense oligonucleotides. *Mol Carcinog* 32:84 – 91.
- Jackson, J.R.; Minton, J.A.; Ho, M.L.; Wei, N.; Winkler, J.D. (1997):** Expression of vascular endothelial growth factor in synovial fibroblasts is induced by hypoxia and interleukin 1beta. *J Rheumatol*, 24:1253-1259.
- Jorgensen, C.; Freemont, A.J.; Holt, P.J. et al. (1997):** Surgery for rheumatoid arthritis. *Clin Rheumatol*, 24: 418-439.
- Kafienah, E.; Bromme, D.; Buttle, D.J.; Croucher, L.J. (1998):** Human cathepsin K cleaves native type I and II collagens at the N-terminal end of the triple helix. *Biochem J* 331: 727-732.
- Kaneko, M.; Tomita, T.; Nakase, T.; Ohsawa, Y.; Seki, H.; Takeuchi, E.; Takano, H. and Shi, K.T. (2001):** Expression of proteinases and inflammatory cytokines in subchondral bone regions in rheumatoid arthritis. *Rheumatology (Oxford)*. 40 : 247 – 255.
- Katsikis, P.D.; Chu, C.Q.; Bernnas, F.M.; Maini, R.N. (1994):** Immuno-regulatory role of interleukin-10 in rheumatoid arthritis. *J Exp Med*, 179: 1517-27.
- Keat, A.C. and Knight, S.C. (1990):** Do synovial cells indicate the cause of reactive arthritis? *J Rheumatol* 17; 1257-1264.

- Kenneth, A. and Kenneth, M. (1994):** Rheumatic diseases. In: Basic and clinical immunology, 7th edition, Stites DP and Terr AI (eds). Lange Medical Publications, P. 438-445.
- Kremmer, J.M.; Lee, J.K.; Glauser, M.P.; et al. (1988):** Along term prospective study of the use of methotrexate in Rheumatoid arthritis. *Arthritis Rheum*, 31: 577-584.
- Lanchbury, J.S. (1994):** In Immunology of connective tissue disease, Parayi, GS, Ed., Dordrecht and Kluwer; 75.
- Leigh, J.P.; Fries, J.F.; Flad, H.D. et al. (1991):** Education level and rheumatoid arthritis, evidence from five data centers. *J Rheumatol*, 18: 24-34.
- Li, Z.; Hou, W.S.; Bromme, D. (2000):** Collagenolytic activity of cathepsin K is specifically modulated by cartilage-resident chondroitin sulfates. *Biochemistry*, 39:529-536.
- Li, Z.; Yasuda, Y.; Li, W.; Bogoy, M.; Katz, N.; Gordon, R.E.; Fields, G.B. and Bromme, D. (2004):** Regulation human cathepsins by glycosaminoglycans. *J. Biol. Chem.*; 279: 5479.
- Lipsky, P.E. (2005):** Rheumatoid arthritis, In: Harrison's principles of internal medicine, 16th edition. Ed by Kasper D, Braunwald E, Fauci A et al., Vol 4 P.
- Lo, V.; Meadows, S.E.; Saseen, J. (2006):** When should COX-2 selective NSAIDs be used for osteoarthritis and rheumatoid arthritis? *J Fam Pract*; 55: 260-2.

- Mallya, F. and Mace, D. (1981):** The assessment of disease activity in RA using multivariate analysis. *Rheum Rehabil*, 20: 14-17.
- McMichael, A.J.; Sasazaki, T.; Mc Devitt, H.O.; et al. (1977):** Increased frequency of HLA-CW3 and HLA-DW4 in rheumatoid arthritis. *Arthritis Rheum* 20: 10376-1042.
- McQueney, M.S.; Amegadzie, B.Y.; D'Alessio, K.; Hanning, C.R.; McLaughlin, M.M.; McNulty, D.; Carr, S.A.; Ijames, C.; Kurdyla, J.; Jones, C.S. (1997):** Autocatalytic activation of cathepsin K. *J Biol Chem*, 272:13955-13960.
- Menezes, A.H.; Van, Gilder, J.C. and Calrk, C.R. (1985):** Odontoid upward migration in RA. *J Neurosurg* 63:500.
- Mort, J.S.; Recklies, A.D. and Poole, A.R. (1984):** Extracellular presence of the lysosomal proteinase cathepsin B in rheumatoid synovium and its activity at neutral pH. *Arthritis Rheum*; 27 : 509 – 15.
- Motyckova, G.; Fisher, D.E. (2002):** Pseudodysostosis: role and regulation of cathepsin K in osteoclast function and human disease. *Curr Mol Med*; 2: 407-421.
- Nakagawa, T.Y.; Brissette, W.H.; Lira, P.D. Griffiths, R.J.; Petrushova, N.; Stock, J.; McNeish, J.D.; Eastman, S.E.; Howard, E.D.; Clarke, S.R.; Rosloniec, E.F.; Elliott, E.A. and Rudensky, A.Y. (1999):** Impaired invariant chain degradation and antigen presentation and diminished collagen – induced arthritis in cathepsin S null mice. *Immunity*, 10 : 207 – 217.
- O'Dell, J.R. (2004):** Therapeutic strategies for rheumatoid arthritis. *N Engl J Med*; 350: 2591-602.

- Ollier, W.E.R.; Mac Gregor, A. (1995):** Genetic epidemiology of rheumatoid arthritis. *Br Med Bull*, 51: 267.
- Olsen, N.J. and Stein, C.M. (2004):** New drugs for rheumatoid arthritis. *N Engl J Med*; 350: 2167-79.
- Orlitz, Z.; Shen, B.; Suancz-Almazoe, H.E. (2002):** Is there a rationale role for combined TNF and IL-1 blocking in arthritis ? *Clin Exp Rheumatol*, 20: 521-5.
- Parak, W.J.; Dannohl, S.; George, M.; Schuler, M.K. Schaumburger, J.; Gaub, H.E.; Muller, O.; Aicher, W.K. (2000):** Metabolic activation stimulates acid production in synovial fibroblasts. *J Rheumatol*, 27:2312-2322.
- Paulus, H.; Toivanen, P.; Shurnik, M. et al. (1996):** monitoring radiographic changes in early rheumatoid arthritis. *J Rheumatol*, 23: 801-805.
- Penny, W.J.; Knight, R.K.; Ress, A.M. et al. (1982):** Oblitrative broncholitides in RA. *Ann Rheum Dis*, 41: 469-473.
- Pincus, T.; Callahan, L.F.; Brooks, R.H. et al. (1989):** Selfreport questionnaire scores in rheumatoid arthritis compared with traditional physical radiographic, and laboratory measures. *Ann Intern Med* 110: 259-66.
- Punturieri, A.; Filippov, S.; Allen, E.; Caras, I.; Murray, R.; Reddy, V.; Weiss, S.J. (2000):** Regulation of elastinolytic cysteine proteinase activity in normal and cathepsin K-deficient human macrophages. *J Exp Med*, 192:789-800.

- Reid, R.; Banerjee, S. and Sciort, R. (2002):** Giant cell tumour. World Health Organization Classification of Tumours. Pathology and Genetics, Tumours of Soft Tissue and Bone; 310-312.
- Rieman, D.J.; McClung, H.A.; Dodds, R.A. et al. (2001):** Biosynthesis and processing of cathepsin K in cultured human osteoclasts. Bone; 28: 282-289.
- Ritchie, D.M.; Boyle, J.A.; Micinne, J.M. et al. (1968):** Clinical studies with an articular index for the assessment of joint tenderness Qusrtey J Med, 37: 393- 406.
- Rocken, C.; Schowotzer, E.; Linke, R.P.; Saeger, W. (1996):** The classification of amyloid deposits in clinicopathological practice. Histopathology 29: 325-335.
- Schett, G.; Redlich, K. and Amolen, J.S. (2003):** The role of osteopetgrin in arthritis. Arthritis Res ther. 3:5:239-245.
- Schindler, R.; Mancilla, J.; Endres, S.; Ghobani, R.; Clark, S.C., Dinanello, C.A. (1990):** Correlation and interactions in the production of interluekin-6 (IL-6), IL-1, and tumor necrosis factors in human blood mononuclear cells. IL-6 suppress IL-1 and TNF. Blood, 75; 40-47.
- Scott, D.L.; Smith, C. and Kingsley, G. (2005):** What are the consequences of early rheumatoid arthritis for the individual? Best Pract Res Clin Rheumatol; 19: 117-36.
- Seigmeith, W.; Ebrel, R.; Knope, H.P. et al. (1987):** RA organ manifestations and complications. Documenta Geigy, CIBA-GEIGY. Limited.

Shingu, M.; Nagai, Y.; Isayama, T.; Naono, T.; Nobunaga, M. (1993): The effect of recombinant tumor necrosis factor in rheumatoid arthritis. Clin Exp Immunol, 94: 145.

Singer, J.M. and Plotz, G.M. (1958): AVIETX-RE, latex serology test for detection of rheumatoid factor. JAMA, 168,180.

Singh, A.R.; Kaur, A.; Anand, N.K.; et al. (2004): Pyknodysostosis visceral manifestations and simian crease. Indian J Pediatr; 71: 453-455.

Skoumal, M.; Lolarz, G. and Klingler, A. (2003): Serum levels of cartilage oligomeric matrix protein and a valuable parameter of disease management in rheumatoid arthritis. Scand J Rheumatol. 32: 156 – 161.

Skoumal M.; Haberhauer, G.; Feyertag, J.; Kittl, E.M.; Bauer, K. and Dunky, A. (2004): Serum levels of protein (COMP) are elevated in rheumatoid arthritis, but not in inflammatory rheumatol reactive arthritis, Raynaud's syndrome, scleroderma, systemic lupus erythematosus, Arthritis Res ? Ther. 6 : 73 – 74.

Stastny, P. (1976): Mixed lymphocyte cultures in rheumatoid arthritis. J Clin Invest, 57: 1148-1152.

Steinrocke, O.; Traeger, G.H. and Bamerman, R.C. (1949): Therapeutic criteria in rheumatoid arthritis. J Amer Med Ass, 140: 659- 664.

Tavares, F.X.; Boncek, V.; Deaton, D.N.; Hassell, A.M.; Long, S.T.; Miller, A.B.; Payne, A.A.; Miller, L.R.; Shewchuk, L.M. and Wells-Knecht, K. et al., (2004): Design of potent, selective and

orally bioavailable inhibitors of cysteine protease cathepsin K. *J. Med. Chem.* 47: 588 – 599.

Tepel, C.; Bromme, D.; Herzog, V. and Brix, K. (2000): Cathepsin K in thyroid epithelial cells: sequence, localization and possible function in extracellular proteolysis of thyroglobulin. *J. Cell. Sci.* 113 : 4487 – 4498.

Tezuka, K.; Tezuka, Y. and Maejima, A. (1994): Molecular cloning of a possible cysteine proteinase predominantly expressed in osteoclasts. *J Biol Chem* 269: 1106-1109.

Troen, B.R. (2004): The role of cathepsin K in normal bone resorption. *Drug News Prespect*; 17: 19-28.

Turk, B.; Turk, V. and Turk, D. (1997): Structural and functional aspects of papain-like cysteine proteinases and their protein inhibitors. *Biol Chem* 378: 141-150.

Unemori, E.N. and Amento, E.P. (1995): Role of cytokines in rheumatoid arthritis. In: Aggarwal BB, Puri RK, eds. *Human cytokines: their role in disease and therapy*. London: Blackwell. Science, 218-36.

Van Der Berg, W.B.; Jooslen, L.A.B.; Kollias, G. (1999): Pathogenesis of joint damage in rheumatoid arthritis. *Am Rheum Dis*, 58: 140.

Votta, B.J.; Levy, M.A.; Badger, A.; Bradbeer, J.; Dodds, R.A.; James, I.E.; Thompson, S.; Bossaard, M.J. Carr, T.; Connor, J.R. et al., (1997): Peptide aldehyde inhibitor of cathepsin K inhibit bone resorption both in vitro and in vivo. *J. Bone Miner. Res.*; 12: 1396-1406.

- Wahl, S.M.; Allen, J.B.; Wong, H.L. (1990):** Antagnoistic and agonistic effects of transforming growth factor B and IL-1 in rhuematoid synovium. *J Immunol*, 145: 2514-19.
- Walsh, D.A. (1999):** Angiogenesis and arthritis. *Rheumatology*, 38:103-112.
- Westedt, M.L.; Herbrunk, P.; Molneu, J.L. et al. (1985):** rheumatoid factors in rheumatoid arthritis and vasculitis. *Rheumatol int*, 5: 209-216.
- Wisnieki, J.J.; Askari, A.D.; Jahreis, G.P. et al. (1981):** Rheumatoid nodulosis, a relatively benign rheumatoid variant. *Arch Inter Med* 141: 615-620.
- Wittrant, Y.; Couillaud, S.; Theoleyre, S.; Dunstan, C.; Heymann, D.; Redini, F. (2002):** Osteoprotegerin differentially regulates protease expression in osteoclast cultures. *Biochem. Biophys. Res. Commun.* 293 : 38 – 44.
- Xia, L.; Kilb, J.; Wex, H.; Lipyansky, A.; Breuil, V.; Stein, L.; Palmer J.T.; Dempster, D.W.; Brömme, D. (1999):** Localization of rat cathepsin K in osteoclasts and resorption pits: inhibition of bone resorption cathepsin K-activity by peptidyl vinyl sulfones. *Biol Chem*, 380:679-687.
- Yokoo, H. and Nkazato, Y. (1998):** Primary localized amyloid tumor of the breast with osseous metaplasia. *Pathol Int.* 48: 545-548.
- Zvaifler, N.J.; Firestein, G.S.; Pannus, and Pannocytes (1994):** Alternative models of joint destruction in rheumatoid arthritis. *Arthritis Rheum*, 37:783-789.